Bank of Montreal
ALXN

Bank of Montreal’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank of Montreal’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-839,239
Closed -$155M – 4053
2021
Q2 		$155M Buy
839,239
+572,425
+215% +$98.3M 0.08% 221
2021
Q1 		$41.2M Sell
266,814
-892,500
-77% -$138M 0.03% 462
2020
Q4 		$181M Sell
1,159,314
-104,562
-8% -$13.4M 0.12% 147
2020
Q3 		$147M Sell
1,263,876
-85,909
-6% -$9.27M 0.12% 148
2020
Q2 		$146M Sell
1,349,785
-218,797
-14% -$23.2M 0.13% 139
2020
Q1 		$142M Buy
1,568,582
+213,477
+16% +$21M 0.16% 121
2019
Q4 		$147M Buy
1,355,105
+878,551
+184% +$94M 0.11% 175
2019
Q3 		$46.7M Buy
476,554
+296,225
+164% +$33.4M 0.04% 380
2019
Q2 		$23.6M Sell
180,329
-128,657
-42% -$16.6M 0.02% 592
2019
Q1 		$41.8M Buy
308,986
+122,849
+66% +$15.3M 0.04% 393
2018
Q4 		$18.1M Sell
186,137
-70,659
-28% -$8.35M 0.02% 585
2018
Q3 		$35.7M Sell
256,796
-412,513
-62% -$51.7M 0.03% 466
2018
Q2 		$83.1M Buy
669,309
+109,765
+20% +$12.8M 0.07% 255
2018
Q1 		$62.4M Sell
559,544
-962,290
-63% -$115M 0.06% 312
2017
Q4 		$182M Buy
1,521,834
+268,053
+21% +$32.6M 0.16% 135
2017
Q3 		$176M Sell
1,253,781
-169,537
-12% -$23M 0.16% 130
2017
Q2 		$173M Buy
1,423,318
+1,228,025
+629% +$143M 0.17% 126
2017
Q1 		$23.7M Sell
195,293
-16,823
-8% -$2.17M 0.02% 508
2016
Q4 		$26M Sell
212,116
-64,365
-23% -$7.88M 0.03% 469
2016
Q3 		$33.9M Sell
276,481
-17,407
-6% -$2.24M 0.04% 388
2016
Q2 		$34.3M Sell
293,888
-14,606
-5% -$2.07M 0.04% 381
2016
Q1 		$42.9M Buy
308,494
+78,330
+34% +$11.5M 0.05% 282
2015
Q4 		$43.9M Buy
230,164
+73,039
+46% +$12.8M 0.05% 276
2015
Q3 		$24.6M Sell
157,125
-2,819
-2% -$514K 0.03% 397
2015
Q2 		$28.9M Buy
159,944
+20,673
+15% +$3.57M 0.03% 410
2015
Q1 		$24.1M Buy
139,271
+2,913
+2% +$527K 0.03% 442
2014
Q4 		$25.2M Buy
136,358
+17,216
+14% +$3.19M 0.03% 412
2014
Q3 		$19.8M Buy
119,142
+23,355
+24% +$3.84M 0.02% 507
2014
Q2 		$15M Buy
95,787
+64,169
+203% +$10.1M 0.02% 617
2014
Q1 		$4.81M Sell
31,618
-57,305
-64% -$9.11M 0.01% 952
2013
Q4 		$11.8M Sell
88,923
-51,869
-37% -$6.22M 0.02% 536
2013
Q3 		$16.4M Buy
140,792
+2,139
+2% +$235K 0.03% 379
2013
Q2 		$12.8M Buy
+138,653
New +$13.4M 0.02% 420

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bank of Montreal's ALXN Position: Q3 2021 in Review

Bank of Montreal sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 839,239 shares — an estimated $155M sold.

Bank of Montreal first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $182M in Q4 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bank of Montreal reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank of Montreal sold 839,239 Alexion Pharmaceuticals shares in Q3 2021, an estimated $155M.
  • Bank of Montreal first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Bank of Montreal's Alexion Pharmaceuticals position peaked at $182M in Q4 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank of Montreal's 13F filing for Q3 2021, filed 12 Nov 2021.